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Survival analysis encompasses investigation of time to event data. In most clinical studies, estimating the cumulative incidence function
(or the probability of experiencing an event by a given time) is of primary interest. When the data consist of patients who experience
an event and censored individuals, a nonparametric estimate of the cumulative incidence can be obtained using the Kaplan–Meier
method. Under this approach, the censoring mechanism is assumed to be noninformative. In other words, the survival time of an
individual (or the time at which a subject experiences an event) is assumed to be independent of a mechanism that would cause the
patient to be censored. Often times, a patient may experience an event other than the one of interest which alters the probability of
experiencing the event of interest. Such events are known as competing risk events. In this setting, it would often be of interest to
calculate the cumulative incidence of a specific event of interest. Any subject who does not experience the event of interest can be
treated as censored. However, a patient experiencing a competing risk event is censored in an informative manner. Hence, the
Kaplan–Meier estimation procedure may not be directly applicable. The cumulative incidence function for an event of interest must
be calculated by appropriately accounting for the presence of competing risk events. In this paper, we illustrate nonparametric
estimation of the cumulative incidence function for an event of interest in the presence of competing risk events using two published
data sets. We compare the resulting estimates with those obtained using the Kaplan–Meier approach to demonstrate the
importance of appropriately estimating the cumulative incidence of an event of interest in the presence of competing risk events.
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Survival analysis is the analysis of data measured from a specific
time of origin until an event of interest or a specified endpoint
(Collett, 1994). For example, in order to determine the incidence of
death due to breast cancer among breast cancer patients, every
patient will be followed from a baseline date (such as date of
diagnosis or date of surgery) until the date of death due to breast
cancer or study closing date. A patient who dies of breast cancer
during the study period would be considered to have an ‘event’ at
their date of death. A patient who is alive at the end of the study
would be considered to be ‘censored’. Thus, every patient provides
two pieces of information: follow-up time and status (i.e., event or
censored). However, a patient can experience an event different
from the event of interest. For example, a breast cancer patient
may die due to causes unrelated to the disease. Such events are
termed competing risk events. Survival data are often summarised
using the cumulative incidence function for an event. The goal of
this paper is to illustrate to the clinical investigator the
nonparametric estimation of the cumulative incidence for an
event of interest in the presence of competing risk events.
GENERAL CONCEPTS IN SURVIVAL ANALYSIS
Clinical studies often focus on estimating the survivor function or
the overall survival probability. This is the probability of being
event-free at least up to a given time. The event is any specific
event of interest. The overall survival probability is estimated
using the person follow-up time and event status. The survival at a
given time is the conditional probability of surviving to a specific
time given that the individual is at risk for the event (such as
mortality) at that time. This is estimated as the ratio of the number
of individuals that are event-free at that time to the number of
individuals that lived event-free at least up to that time.
Henceforth, when referring to survival at a given time, we in fact
mean survival conditional upon being at risk at that time.
For example, let us consider the event of interest to be death.
Suppose 100 breast cancer patients lived for at least 1 year
following surgery and five patients died at the end of the first year.
The estimated survival at 1 year is 95%. This estimate is the
survival probability conditional upon the fact that the 95 surviving
patients were all at risk at 1 year. Suppose at 2 years, 10 more
patients die. The estimated survival at 2 years is 85/95¼89.5%.
The estimated overall survival up to and including 2 years is the
probability of having survived the first year and the second year.
This is calculated as 95*89.5¼85%. Therefore, the overall survival
or the probability of surviving up to 2 years is 85%. This is the
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(Kaplan and Meier, 1958).
Equivalently, we can consider estimating the incidence of
mortality among patients with breast cancer. In the above example,
the estimated incidence of mortality at 1 year is five out of 100
patients, that is, 5%. The probability of dying at 2 years is the
probability of living past the first year and dying during the second
year. Note that 95 of 100 patients survived past the first year, and
10 of these 95 patients died in the second year. Therefore, the
estimated incidence of mortality at 2 years is 95/100*10/95¼10%.
The cumulative incidence of mortality up to a given time is the
probability that an individual dies by that time. This is the sum of
mortality incidences occurring up to that time. Therefore, the
cumulative incidence of mortality at 2 years is the sum of mortality
incidences in the first and second years, that is, 5þ10¼15%. This
is simply the converse of survival. In other words, the cumulative
incidence of an event at a given time is one minus the overall
survival probability at that time.
An investigator may be interested in examining outcomes other
than mortality, such as incidence of disease recurrence or
incidence of a second primary cancer. In this scenario, a patient
is followed from a baseline time (such as date of diagnosis or date
of treatment) until the outcome of interest. In order to estimate the
incidence of ovarian cancer among breast cancer patients, any
patient who does not develop ovarian cancer is treated as
censored. If a woman has not developed ovarian cancer by the
study closing date, she would be considered censored. If a woman
dies of breast cancer prior to developing ovarian cancer, she would
be considered censored at her date of death when evaluating the
incidence of ovarian cancer. However, the latter type of censoring
is informative since this patient is censored due to the occurrence
of an intervening event (mortality). Such intervening events are
known as ‘competing risk events’. Events other than death can also
be competing risk events. Suppose a breast cancer patient
undergoes a prophylactic oophorectomy after surgery for breast
cancer. This prophylactic treatment substantially reduces the
probability of developing ovarian cancer, and hence is treated as a
competing risk event when calculating ovarian cancer incidence.
Thus, a competing risk event may preclude the onset of the event
of interest, or may modify the probability of the onset of the event
of interest. Other types of data may also arise in practice. For
example, a patient may also experience multiple or repeated events
such as cancer in a different site (for example, primary melanoma
in a breast cancer patient), second primary cancer or disease
recurrence. In this paper, we restrict ourselves to competing risk
events where the follow-up duration of a patient ends at the onset
of the first event, and do not focus on multiple or repeated events
occurring in a patient. We first describe the two illustrative
examples, and then demonstrate the estimation of cumulative
incidence of an event of interest.
ILLUSTRATIVE EXAMPLES
Fanconi anaemia (FA) data
A total of 755 patients were identified through the International
Fanconi Anaemia Registry at The Rockefeller University (Kutler
et al, 2003). Complementation group was determined for a subset
of these patients by cDNA transduction and/or mutation analysis.
The patients were followed from their date of birth (i.e., the date of
onset of FA) until the onset of haematologic malignancy (HM) or
the last follow-up date (in months). Several patients died due to
FA-related complications without developing HM. Hence, death
prior to the onset of HM is a competing risk event.
Some of the FA patients developed other malignancies during
their follow-up period. In order to simplify the presentation, and
to demonstrate the calculations of interest, here we focus on HM as
the event of interest, and death prior to the onset of HM as the
competing risk event, and do not consider information on other
malignancies (i.e., multiple or repeated events).
Breast cancer data
This data set consists of 305 women diagnosed with breast cancer
at any age, self-identified as Ashkenazi Jewish (Robson et al, 1999).
All these women underwent breast-conservation therapy at
MSKCC between January 1980 and December 1990. The tissue
samples were examined for the presence of a 185delAG or
5382insC mutation in BRCA1 and 6174delT mutation in BRCA2,
the mutations commonly occurring in Ashkenazi Jewish indivi-
duals. These women were followed from their date of breast-
conservation therapy until death due to breast cancer or the last
follow-up date. Several patients died due to causes other than
breast cancer. Hence, death due to other causes is a competing risk
for breast cancer specific mortality.
METHODS
In this section, we describe estimating the cumulative incidence
function for an event of interest in the presence of competing risk
events. Below we first discuss nonparametric estimation using the
Kaplan–Meier approach. Patients who are alive at the end of the
study as well as patients experiencing competing risk events are all
considered censored in the same manner under this estimation
approach. The Kaplan–Meier approach is based on the premise
that the censoring is noninformative, that is, independent of the
event of interest. However, the presence of competing risk events
result in informative censoring. We next outline how to
nonparametrically estimate the cumulative incidence of the event
of interest by differentiating between the informative and
noninformative censoring.
The Kaplan–Meier estimate of cumulative incidence
The Kaplan–Meier approach (Kaplan and Meier, 1958), also
known as the product-limit estimate, provides a nonparametric
estimate of the overall survival probability of an event of interest.
The cumulative incidence is then calculated as one minus this
survival probability. Every patient in the data set has a follow-up
time and status (event or censored). The follow-up times where an
event has occurred are ordered from the smallest to the largest
(noting that there can be ties since more than one patient may have
the event at the same follow-up time). Consider consecutive event
times tj 1 and tj. The Kaplan–Meier estimate of the overall
survival probability up to event time tj proceeds as follows. Let nj
be the number of event-free individuals up to time tj. Suppose dj
events have occurred at time tj. The estimated survival probability
at time tj is given by the ratio (nj dj)/nj. The overall survival
probability up to time tj, denoted S(tj), is the probability of
surviving up to and including time tj. Therefore, the overall
survival probability up to tj is estimated as the product of the
probabilities of survival in all the previous times: SðtjÞ  Q
ni   di=ni ðÞ ¼ Sðtj   1Þ  nj   dj=nj
  
; where the product is
over i¼1, y, j. The overall survival probability for any time
between tj 1 and tj is the same as S(tj 1), the survival probability
up to, but not including, tj.
In the FA data set, it is of interest to estimate the cumulative
incidence of HM among FA patients. In order to calculate this, we
use the Kaplan–Meier method outlined above to estimate the HM-
free survival probability, that is, the probability that an FA patient
will not develop HM. We then calculate the cumulative incidence
as one minus this survival probability.
Table 1a illustrates a subset of the Fanconi data set. The
individuals were first sorted by their follow-up times (column 2;
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at the youngest age (4 months). Patients 744 and 745 had HM at
495 and 498 months, respectively, after the onset of FA. Patient 746
was followed for 509 months from birth and was alive at this
follow-up time with no diagnosis of HM. Patient 747 died 522
months after the onset of FA without ever being diagnosed with
HM. For the Kaplan–Meier analysis, patients 744 and 745 are
considered to have had the event (i.e., HM), while patients 746 and
747 are both considered censored at their follow-up times. Patient
747 died prior to the onset of HM, while patient 746 was alive and
not diagnosed with HM. However, in the Kaplan–Meier analysis,
both these patients will be considered as censored in the same
manner.
The estimation of HM-free survival is illustrated in Table 1b.
Suppose we are interested in estimating the overall HM-free
survival up to time tj¼498 months. The previous event occurred
at time tj 1¼495 months. There were 11 patients with follow-up
times of at least 498 months, namely there are 11 patients who
lived up to 498 months from the onset of FA and did not develop
HM; thus, here nj¼11. At 498 months, patient 745 developed HM;
thus, dj¼1 in this interval. The HM-free survival probability
estimate at 498 months is (nj dj)/nj¼(11 1)/11¼90.9% (column
4; Table 1b). The overall HM-free survival probability up to 498
months is the probability of surviving without a diagnosis of HM
up to 495 months multiplied by the probability of being HM-free at
498 months. The estimated HM-free survival up to 495 months is
S(tj 1)¼41.2%. Hence, the overall HM-free survival probability
estimate up to 498 months is S(tj)¼41.2*90.9¼37.5% (column 5;
Table 1b). The overall HM-free survival probabilities for the other
time points can be estimated in a similar manner.
The cumulative disease incidence of developing HM by time
tjþ1 is one minus the HM-free survival probability, that is,
1 S(tjþ1). This can be seen in the last column of Table 1b. For
example, the HM-free survival or the probability of not developing
HM up to 498 months from birth is 41.2%. This is equivalent to a
58.8% probability of developing HM (or cumulative incidence of
HM) by this time. Figure 1 provides a graphical representation of
the resulting estimates. The estimates derived using the Kaplan–
Meier approach are shown using the solid line.
Table 2a provides a subset of the breast cancer patients. A
graphical representation of the cumulative breast cancer-specific
mortality of these patients, estimated using the Kaplan–Meier
approach, is given in Figure 2 using a solid line.
Cumulative incidence estimation in the presence of
competing risk events
In this section, we illustrate nonparametric estimation of
cumulative incidence of the event of interest taking into account
the informative nature of censoring due to competing risks. The
cumulative incidence, accounting for competing risk events, is
estimated in a two-step process (Kalbfleisch and Prentice, 1980;
Marubini and Valsecchi, 1995). In the first step, we calculate the
Kaplan–Meier estimate of the overall survival from any event. Is it
Table 1 Illustration of the cumulative incidence of haematologic malignancy (HM) for the Fanconi anaemia (FA) data set using the Kaplan–Meier method
(a) A subset of FA patients
a
Patient number Follow-up time Status HM status
1 0.003 Dead C
2 0.003 Dead C
y
21 4 HM E
y
744 495 HM E
745 498 HM E
746 509 Alive C
747 522 Dead C
748 538 Alive C
749 544 HM E
750 546 HM E
751 566 Alive C
752 572 Alive C
753 582 HM E
754 587 Dead C
755 599 Alive C
(b) Kaplan–Meier survival probability estimates
b
Time interval (tj) # at risk (nj) # of events (dj) Survival probability
((nj dj)/nj)( % )
Overall survival
(S(tj)) (%)
Incidence 1 S(tj)
0– 755 0 100 100 0
4– 735 1 99.9 99.9 0.1
y 44.9 55.1
495– 12 1 91.7 41.2 58.8
498– 11 1 90.9 37.5 62.5
544– 7 1 85.7 32.1 67.9
546– 6 1 83.3 26.8 73.2
582– 3 1 66.7 17.8 82.2
HM¼haematologic malignancy; C¼censored; E¼event.
aThe follow-up time (in months), event status (affected with HM, dead or alive) and HM status (event if patient has
HM, censored otherwise).
bKaplan–Meier survival probability estimates for the subset of the FA patients listed in (a). Column 1 gives the event times (in months). Column 2
shows the number of individuals at risk before that event time. Column 3 is the number of patients diagnosed with HM at that time. Column 4 is the estimated survival probability
between that event time and the next. Column 5 provides the overall survival probability using the Kaplan–Meier method. Column 6 gives the cumulative incidence of HM.
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competing risk event are considered ‘events’. In the second step,
the conditional probabilities of experiencing the event of interest
are calculated. The cumulative incidences are estimated using
these probabilities. The step-by-step calculations are detailed
below.
Step 1:
Here we calculate the overall survival probability of being
‘event-free’.
1. An ‘event’ is any event – the onset of the event of interest or the
competing risk event. Anyone not experiencing the ‘event’ (i.e.
event free) is considered censored.
2. The Kaplan–Meier survival probabilities corresponding to the
‘event’ are calculated as described in the previous section.
Step 2:
Here, we calculate the cumulative probability of experiencing
the event of interest.
1. Consider the interval between event-of-interest times tj 1 and
tj. (Note that a competing risk event may occur in this interval.)
2. The probability of failure for the event of interest is defined as
one minus the probability of survival given by
h(tj)¼1 (nj dj)/nj¼dj/nj, where nj is the number of indivi-
duals at risk before time tj and dj is the number of events of
interest occurring at time tj.
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Figure 1 Cumulative incidence of HM in FA patients. The bold line
shows the cumulative incidence calculated using the Kaplan–Meier
approach without accounting for competing risk events. The dashed line
shows the cumulative incidence, after adjusting for competing risk. The
dotted line shows the cumulative incidence of the competing risk event
(i.e. death occurring prior to the event of interest).
Table 2 Illustration of the cumulative incidence of breast cancer-specific mortality for the breast cancer data set using the competing risk approach
(a) A subset of breast cancer patients
a
Patient number Follow-up time Status BC status
1 7 Alive C
2 10 Dead-BC E
3 14 Alive C
4 16 Dead-BC E
5 18 Dead-Other CR
6 23 Dead-BC E
7 24 Alive C
8 26 Dead-Other CR
9 27 Dead-BC E
y
(b) An illustration of estimating cumulative incidence accounting for competing risk for the subset of breast cancer patients listed above (a)
Step 1
Time interval (tj) # at risk (nj) # of events (dj) Survival probability
((nj dj)/nj)( % )
Overall survival
(S(tj)) (%)
0– 305 0 100 100
10– 304 1 99.7 99.7
16– 302 1 99.7 99.3
18– 301 1 99.7 99.0
23– 300 1 99.7 98.7
26– 298 1 99.7 98.3
27– 297 1 99.7 98.0
y
Step 2
Time interval (tj) # at risk (nj) # of events (dj1) Failure probability
(h1(tj)) (%)
Survival up to time tj
(S(tj 1)) (%)
Incidence
(h1(tj)*S(tj 1)) (%)
Cumulative incidence
(I(tj)) (%)
0- 305 0 0 100 0 0
10- 304 1 0.3 100 0.3 0.3
16- 302 1 0.3 99.7 0.3 0.6
23- 300 1 0.3 99.0 0.3 0.9
27- 297 1 0.3 98.3 0.3 1.2
y
C¼censored; E¼event; CR¼competing risk event.
aThe follow-up time (in months), event status (dead due to breast cancer, dead due to causes other than breast cancer, or
alive), and breast cancer death status (event if patient died due to breast cancer, censored otherwise).
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‘event’ (both the event of interest and the competing risk event)
up to, but not including, time tj. This can be obtained from the
calculations in Step 1, and is denoted by S(tj 1).
4. Accounting for competing risk, the incidence of the event of
interest for this interval is estimated as the product
h(tj)*S(tj 1). This can be interpreted as the joint probability
of experiencing the event of interest in this time interval given
that the individuals survived both the event of interest and the
competing risk event in all prior intervals.
5. The cumulative incidence to the end of this time interval is
defined as the sum of the incidence in this interval and all
previous time intervals.
The cumulative incidence of every distinct type of failure can be
calculated as described above. The cumulative incidence of any
event by a given time will be the sum of the incidence of all distinct
failures by that time.
The estimation of the cumulative incidence of breast cancer-
specific mortality is outlined in Table 2b. The overall survival from
any event given under Step 1 of Table 2b is calculated using the
Kaplan–Meier approach. In Step 2 of Table 2b, we calculate the
probability of the event of interest, that is, death due to breast
cancer, in various time intervals. The probability of death due to
breast cancer from 10 months up to 16 months is 1/304¼0.3%.
From Step 1 we know that the probability of surviving (i.e. not
dying due to breast cancer or due to any other cause) up to but not
including 10 months is 100%. Therefore, the incidence of death
due to breast cancer from 10 months up to 16 months is
100% 0.3%¼0.3%. One out of 302 individuals at risk died due to
breast cancer at 16 months follow-up time. The next death due to
breast cancer occurred at 23 months (patient 6). Therefore, the
probability of death due to breast cancer from 16 months up to 23
months is 1/302¼0.3%. However, a competing risk event occurred
at 18 months (patient 5 died due to other causes). From Step 1, the
cumulative probability of surviving any event (i.e. not dying due to
breast cancer or due to any other cause) from 18 months up to 23
months is 99%. Therefore, the incidence of the event of interest
(death due to breast cancer) from 16 months up to 23 months is
0.3% 99%¼0.3%. Hence, the cumulative incidence of the event
of interest up to 23 months is the sum of the incidences in all
intervals prior to 23 months, that is 0%þ0.3%þ0.3%¼0.6%.
Figure 2 illustrates the cumulative incidence corresponding to
death due to breast cancer. The long dashed line is the cumulative
incidence of the event of interest, that is, death due to breast
cancer. The dotted line is the cumulative incidence of the
competing risk event, that is, death due to other causes. Similarly,
the cumulative incidence of HM and cumulative mortality prior to
the onset of HM for the FA data set are shown in Figure 1 using
long dashed and dotted lines, respectively.
It is to be noted that the cumulative incidence of any event is the
sum of the cumulative incidence of the event of interest and the
cumulative incidence of the competing risk events. Therefore, the
cumulative mortality among the breast cancer patients is the sum
of the cumulative breast cancer-specific mortality and the
cumulative mortality due to causes other than breast cancer.
Similarly, in the FA data set, the cumulative incidence of
experiencing any event (i.e. developing HM or death prior to the
onset of HM) is simply the sum of cumulative incidence of HM and
the cumulative mortality without the onset of HM.
Cumulative incidence of multiple groups
Often it is of interest to estimate (and compare) the cumulative
incidences between two or more groups. For example, in the FA
data set, it may be of interest to estimate the incidence of HM in
the various complementation groups. Likewise, in the breast
cancer data, it may be of interest to estimate breast cancer-specific
mortality for those with and without a BRCA mutation. This is
carried out by first dividing the sample into the subgroups of
interest. The cumulative incidences of the event of interest are then
calculated for each group separately as outlined above. Table 3
provides the cumulative incidences of HM using the Kaplan–
Meier approach as well as the competing risks approach,
separately for patients in complementation groups FA-A, -C, -G
and other patients (O¼mostly nontyped patients and a small
number of patients in uncommon complementation groups).
Likewise, Table 4 provides breast cancer-specific mortality for
patients with and without a BRCA mutation using the two
methods.
The cumulative incidences in the various groups can be
compared using nonparametric tests, namely the log-rank test
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Figure 2 Cumulative breast cancer-specific mortality. The bold line
shows the cumulative incidence calculated using the Kaplan–Meier
approach without accounting for competing risk events. The dashed line
shows the cumulative incidence, after adjusting for competing risk. The
dotted line shows the cumulative incidence of the competing risk event (i.e.
death due to other causes).
Table 3 Cumulative incidence of haematologic malignancy in Fanconi
anaemia patients obtained using the Kaplan–Meier (KM) approach by not
adjusting for competing risk events, and estimated by adjusting for
competing risk events (CR)
Overall (%) A (%) C (%) G (%) O (%)
N (HEM) 755 (120) 207 (30) 78 (19) 46 (10) 414 (60)
% Censored KM 84 86 76 78 86
CR 58 67 44 57 55
10 year KM 6.3 5 15 11 5
CR 5.9 4 11 7 5
20 year KM 22.6 20 42 32 19
CR 17.8 15 27 21 14
30 year KM 39.0 45 53 45 34
CR 27.8 31 32 31 23
40 year KM 47.8 52 68 45 44
CR 31.8 34 35 31 27
Column 3 (‘Overall’) shows the cumulative incidence for all the 755 patients.
Columns 4, 5, 6 and 7 show the cumulative incidence estimates for patients in
complementation groups A, C, G and O (mostly nontyped patients and a small
number of patients in uncommon complementation groups). The sample size is
denoted N. The number of haematologic malignancy events is denoted by HEM and
is given in parentheses in the second row.
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on the Kaplan–Meier approach or a modified w
2 test (Gray, 1988)
when calculating incidences in the presence of competing risks.
The cumulative incidence estimation methods outlined above are
nonparametric, that is, these estimates are not based upon any
specific model. Alternative model-based approaches can also be
utilized to estimate cumulative incidences of specific events,
adjusting for prognostic factors of interest. Under the assumption
of noninformative censoring, the Cox proportional hazards model
(Cox, 1972) can be used. In the presence of competing risk events,
a modified Cox proportional hazards model or the competing risk
regression approach has been developed by Fine and Gray (1999).
We do not detail these methods here, but refer the reader to the
references provided above.
DISCUSSION
In this paper, we have focused on the estimation of cumulative
incidence function for an event of interest in the presence of
competing risk events. We have outlined nonparametric estima-
tion using a Kaplan–Meier approach, which assumes noninfor-
mative censoring, as well as an alternative approach that accounts
for informative censoring. Calculating the standard error of the
estimates and the corresponding confidence intervals are dis-
cussed by Collett (1994) and Marubini and Valsecchi (1995). The
Kaplan–Meier approach results in one curve that portrays the
estimated cumulative probability of the event of interest (i.e. one
minus the estimated survival probability) with a jump in the curve
corresponding to the occurrence of an event of interest at a specific
time. The competing risk approach generates two curves, one
representing the event of interest and the other representing the
competing risk event. The curve representing the cumulative
incidence of the event of interest has jumps at times where an
event of interest occurs. Likewise, the curve corresponding to the
incidence of the competing risk event has jumps at times where
competing risk events occur.
The estimated cumulative incidence of an event of interest
derived using the Kaplan–Meier approach is, in general, larger
than estimates obtained when accounting for competing risks. This
is due to the following reason. In the Kaplan–Meier estimation
approach, when an individual experiences a competing risk event,
this individual is treated as censored and is eliminated from the
risk set. On the other hand, in the competing risk approach, this
individual is an event in the calculation of the overall survival
probability of any event (Step 1). The estimated overall survival of
any event is lowered when this individual experiences a competing
risk event. Recall that the incidence of the event of interest in a
specific time interval is the probability of surviving any event up to
that time interval and experiencing the event of interest in that
interval. Since the overall survival is reduced when any event
occurs, the resulting incidence of the event of interest is reduced as
well.
In the FA data set, a total of 120 out of the 755 patients were
diagnosed with HM. The remaining 635 patients not diagnosed
with HM were considered censored under the Kaplan–Meier
approach. The estimated cumulative incidences using the Kaplan–
Meier approach are 6.3, 22.6, 39.0 and 47.8% at 10, 20, 30 and 40
years, respectively, since birth (Table 3). A total of 199 out of the
635 ‘censored’ patients died prior to the onset of HM. The
estimated cumulative incidences of HM using the competing risk
approach are 5.9, 17.8, 27.8 and 31.8%, respectively, at 10, 20, 30
and 40 years since the diagnosis of FA. Thus, the estimates are
lower when accounting for the competing risk event. Table 4
summarises the cumulative incidence estimates for the breast
cancer data set. A total of 43 out of the 305 patients died due to
breast cancer. The remaining 262 individuals were considered
censored when estimating the cumulative mortality without
accounting for competing risk using the Kaplan–Meier approach.
Of these 262 individuals, 25 women died due to causes unrelated to
breast cancer. The estimated cumulative breast cancer-specific
mortality without accounting for competing risk are 0.3, 4.4, 14.2
and 18.6% at 1, 5, 10 and 15 years, respectively. The corresponding
estimates when accounting for competing risks are 0.3, 4.3, 13.6
and 17.6%, respectively. As before, it is evident that the estimates
are lower when accounting for the competing risk event.
In certain situations, the cumulative incidence of an event of
interest estimated using the Kaplan–Meier approach and the
competing risk approach can be similar. The difference between
the estimated breast cancer specific-mortality derived from the
Kaplan–Meier and the competing risk approach is small for the
breast cancer data set. However, the incidence of HM estimated
using the Kaplan–Meier approach is substantially larger than that
derived from the competing risk approach. Fanconi anaemia
patients are at increased risk for HM as well death, relative to the
general population (Kutler et al, 2003), due to their underlying
disease, that is, FA. It is, therefore, important in this setting to
appropriately account for the competing causes of risk when
estimating the cumulative incidence of HM. On the other hand,
death due to other causes may not be related to having
breast cancer unlike breast cancer-specific mortality. In this
case, ignoring the informative censoring mechanism does not
substantially influence the estimates of breast cancer-specific
mortality.
When there are no competing risk events, that is, when there is
only one type of failure, the estimate of the cumulative incidence of
the event derived using the Kaplan–Meier approach and the
competing risk approach will be identical. Similarly, in the setting
when it is of interest to estimate the cumulative incidence of the
first event in the presence of multiple types of failure, there are no
competing risk events. This is because any event that occurs
subsequent to the first event is not relevant to the analysis. Only
those patients not experiencing any event will be censored. For
example, suppose an FA patient dies after experiencing HM, and it
is of interest to estimate the cumulative incidence of the first event
(HM or death). In this setting, only the time to HM would be of
interest for this patient in the cumulative incidence calculation.
The estimated cumulative incidence of the first event obtained
Table 4 Breast cancer-specific mortality obtained using the Kaplan–
Meier (KM) approach by not adjusting for competing risk events, and
estimated by adjusting for competing risk events (CR)
Mortality due to breast cancer
Overall
(%)
BRCA mutation
(%)
No mutation
(%)
N (BCSS) 305 (43) 28 (8) 276 (35)
% Censored KM 86 71 87
CR 77 64 79
1 year KM 0.3 3.6 0.0
CR 0.3 3.6 0.0
5 year KM 4.4 10.9 3.7
CR 4.3 10.7 3.7
10 year KM 14.2 28.4 12.8
CR 13.6 27.0 12.3
15 year KM 18.6 37.3 16.7
CR 17.6 35.2 15.9
Column 3 (‘Overall’) shows the cumulative incidence for all the 305 breast cancer
patients. Columns 4 and 5 show the cumulative incidence estimates for patients with
and without a BRCA mutation. The sample size is denoted N. The number of breast
cancer-specific deaths is denoted BCSS and is given in parentheses in the second row.
One patient without a BRCA mutation had missing death status and hence was
excluded from the analysis.
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obtained using the competing risk approach.
One minus the Kaplan–Meier survival probability can be
interpreted as the cumulative probability of failure. The cumula-
tive incidence of an event of interest estimated by accounting for
competing risk events is the probability of experiencing the event
of interest by a given time and not experiencing a competing risk
event by this time. One minus the cumulative incidence is the
probability of surviving the event of interest up to a specific time.
This can occur if the patient did not experience both the event of
interest and the competing risk event, or if the patient had the
competing risk event before the onset of the event of interest. As a
result, one minus the cumulative incidence adjusted for competing
risk events cannot be interpreted as the probability of surviving
any event.
The topics of competing risk events and the estimation of
cumulative incidence of an event of interest have been discussed
by several authors. Gail (1975) reviews the theoretical concepts
underlying the estimation of cumulative incidence of an event
using a variety of models. Prentice et al (1978) discuss likelihood
inference to examine the effect of prognostic factors on the
event of interest in the presence of competing risk events. Pepe
and Mori (1993) describe various probability models for
summarising competing risk data. Tai et al (2001) developed a
method to estimate the cumulative incidence of a specific event
based on an extension of the Cox proportional hazards regression
model. They compare their estimates to the Kaplan–Meier
estimate of cumulative incidence as well as the cumulative
incidence accounting for competing risk as described above. Their
findings show that the estimates obtained using the Kaplan–Meier
approach are numerically larger than those accounting for
competing risk events. Clark et al (2003a,b) and Bradburn et al
(2003a,b) provide a detailed tutorial review of various survival
analysis concepts, including a brief summary of competing risk
analysis.
Several softwares are available to estimate the overall survival
probabilities and cumulative incidence of an event of interest. The
Kaplan–Meier estimate of survival probability can be easily
obtained using standard statistical analysis softwares including R
(http://www.r-project.org), S-plus (Insightful Corp., 2003), SAS
(SAS Institute, 2002) and SPSS (SPSS Inc., 2003). Software has been
made available in R by Gray (1988; http://biowww.dfci.harvard.e-
du/~gray/) for obtaining the estimate of cumulative incidence in
the presence of competing risk events.
In summary, it is important to account for competing
risk events when estimating disease incidence. Failure to account
for such competing events results in an overestimate of the
cumulative incidences. This could be substantial when the
competing risk event is related to or is a result of the underlying
disease.
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